Literature DB >> 34713772

Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.

Kevin Duff1, Kayla R Suhrie1, Dustin B Hammers1, Ava M Dixon1, Jace B King2, Vincent Koppelmans3, John M Hoffman4.   

Abstract

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has been associated with commonly used biomarkers of Alzheimer's disease (AD). However, prior studies have typically utilized small and poorly characterized samples, and they have not analyzed the subtests of the RBANS. The current study sought to expand on prior work by examining the relationship between the Indexes and subtest scores of the RBANS and three AD biomarkers: amyloid deposition via positron emission tomography, hippocampal volume via magnetic resonance imaging, and APOE ε4 status. One-hundred twenty-one older adults across the AD continuum (intact, amnestic Mild Cognitive Impairment, mild AD), who were mostly Caucasian and well-educated, underwent assessment with the RBANS and collection of the three biomarkers. Greater amyloid deposition was significantly related to lower scores on all five Indexes and the Total Scale score of the RBANS, as well as 11 of 12 subtests. For bilateral hippocampal volume, significant correlations were observed for 4 of the 5 Indexes, Total Scale score, and 9 of 12 subtests, with smaller hippocampi being related to lower RBANS scores. Participants with at least one APOE ε4 allele had significantly lower scores on 3 of the 5 Indexes, Total Scale score, and 8 of the 12 subtests. In this sample of participants across the dementia spectrum, most RBANS Indexes and subtests showed relationships with the amyloid deposition, hippocampal volumes, and APOE status, with poorer performance on the RBANS being associated with biomarker positivity. Although memory scores on the RBANS have traditionally been linked to biomarkers in AD, other Index and subtest scores also hold promise as indicators of AD. Replication in a more diverse sample is needed.

Entities:  

Keywords:  Alzheimer’s disease; Mild Cognitive Impairment; biomarkers; neuropsychology

Year:  2021        PMID: 34713772      PMCID: PMC9271322          DOI: 10.1080/13854046.2021.1995050

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   4.373


  63 in total

1.  Automatically parcellating the human cerebral cortex.

Authors:  Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Cereb Cortex       Date:  2004-01       Impact factor: 5.357

2.  Predicting change with the RBANS in a community dwelling elderly sample.

Authors:  Kevin Duff; Mike R Schoenberg; Doyle Patton; James Mold; James G Scott; Russell L Adams
Journal:  J Int Neuropsychol Soc       Date:  2004-10       Impact factor: 2.892

3.  Neuroimaging signatures and cognitive correlates of the montreal cognitive assessment screen in a nonclinical elderly sample.

Authors:  Robert Paul; Elizabeth M Lane; David F Tate; Jodi Heaps; Dana M Romo; Erbil Akbudak; Jennifer Niehoff; Thomas E Conturo
Journal:  Arch Clin Neuropsychol       Date:  2011-06-04       Impact factor: 2.813

4.  Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease.

Authors:  Edmond Teng; Michael Ward; Paul T Manser; Sandra Sanabria-Bohorquez; Rebecca D Ray; Kristin R Wildsmith; Suzanne Baker; Geoffrey A Kerchner; Robby M Weimer
Journal:  Neurobiol Aging       Date:  2019-06-06       Impact factor: 4.673

5.  Relation of the Repeatable Battery for Assessment of Neuropsychological Status to measures of daily functioning in dementia.

Authors:  Bryan M Freilich; Leon A Hyer
Journal:  Psychol Rep       Date:  2007-08

6.  Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers.

Authors:  Kevin Duff; Joy D Humphreys Clark; Sid E O'Bryant; James W Mold; Randolph B Schiffer; Patricia B Sutker
Journal:  Arch Clin Neuropsychol       Date:  2008-07-17       Impact factor: 2.813

7.  The Minimum Clinically Important Difference in the Repeatable Battery for the Assessment of Neuropsychological Status.

Authors:  Rachel Phillips; Gao Qi; Simon Lowes Collinson; Audrey Ling; Lei Feng; Yin Bun Cheung; Tze-Pin Ng
Journal:  Clin Neuropsychol       Date:  2015-11-07       Impact factor: 3.535

8.  Generalizability of reliable change equations for the RBANS over one year in community-dwelling older adults.

Authors:  Dustin B Hammers; Kayla R Suhrie; Sariah M Porter; Ava M Dixon; Kevin Duff
Journal:  J Clin Exp Neuropsychol       Date:  2020-03-26       Impact factor: 2.475

9.  Preliminary Validation of the Global Neuropsychological Assessment in Alzheimer's Disease and Healthy Volunteers.

Authors:  Lauren T Olson; Alan Smerbeck; Christina M Figueroa; Jeremy M Raines; Kinga Szigeti; David J Schretlen; Ralph H B Benedict
Journal:  Assessment       Date:  2021-02-09

10.  The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.

Authors:  Su Yeon Park; Byung Hyun Byun; Byung Il Kim; Sang Moo Lim; In Ok Ko; Kyo Chul Lee; Kyeong Min Kim; Yu Kyeong Kim; Jun-Young Lee; Seon Hee Bu; Jung Hwa Kim; Dae Yoon Chi; Jeong Ho Ha
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.